Literature DB >> 29384031

Racial and Ethnic Disparities in Meeting MTM Eligibility Criteria Based on Star Ratings Compared with the Medicare Modernization Act.

Christina A Spivey1, Junling Wang1, Yanru Qiao1, Ya-Chen Tina Shih2, Jim Y Wan3, Julie Kuhle4, Samuel Dagogo-Jack3, William C Cushman5, Marie Chisholm-Burns1.   

Abstract

BACKGROUND: Previous research found racial and ethnic disparities in meeting medication therapy management (MTM) eligibility criteria implemented by the Centers for Medicare & Medicaid Services (CMS) in accordance with the Medicare Modernization Act (MMA).
OBJECTIVE: To examine whether alternative MTM eligibility criteria based on the CMS Part D star ratings quality evaluation system can reduce racial and ethnic disparities.
METHODS: This study analyzed the Beneficiary Summary File and claims files for Medicare beneficiaries linked to the Area Health Resource File. Three million Medicare beneficiaries with continuous Parts A, B, and D enrollment in 2012-2013 were included. Proposed star ratings criteria included 9 existing medication safety and adherence measures developed mostly by the Pharmacy Quality Alliance. Logistic regression and the Blinder-Oaxaca approach were used to test disparities in meeting MMA and star ratings eligibility criteria across racial and ethnic groups. Multinomial logistic regression was used to examine whether there was a disparity reduction by comparing individuals who were MTM-eligible under MMA but not under star ratings criteria and those who were MTM-eligible under star ratings criteria but not under the MMA. Concerning MMA-based MTM criteria, main and sensitivity analyses were performed to represent the entire range of the MMA eligibility thresholds reported by plans in 2009, 2013, and proposed by CMS in 2015. Regarding star ratings criteria, meeting any 1 of the 9 measures was examined as the main analysis, and various measure combinations were examined as the sensitivity analyses.
RESULTS: In the main analysis, adjusted odds ratios for non-Hispanic blacks (backs) and Hispanics to non-Hispanic whites (whites) were 1.394 (95% CI = 1.375-1.414) and 1.197 (95% CI = 1.176-1.218), respectively, under star ratings. Blacks were 39.4% and Hispanics were 19.7% more likely to be MTM-eligible than whites. Blacks and Hispanics were less likely to be MTM-eligible than whites in some sensitivity analyses. Disparities were not completely explained by differences in patient characteristics based on the Blinder-Oaxaca approach. The multinomial logistic regression of each main analysis found significant adjusted relative risk ratios (RRR) between whites and blacks for 2009 (RRR = 0.459, 95% CI = 0.438-0.481); 2013 (RRR = 0.449, 95% CI = 0.434-0.465); and 2015 (RRR = 0.436, 95% CI = 0.425-0.446) and between whites and Hispanics for 2009 (RRR = 0.559, 95% CI = 0.528-0.593); 2013 (RRR = 0.544, 95% CI = 0.521-0.569); and 2015 (RRR = 0.503, 95% CI = 0.488-0.518). These findings indicate a significant reduction in racial and ethnic disparities when using star ratings eligibility criteria; for example, black-white disparities in the likelihood of meeting MTM eligibility criteria were reduced by 55.1% based on star ratings compared with MMA in 2013. Similar patterns were found in most sensitivity and disease-specific analyses.
CONCLUSIONS: This study found that minorities were more likely than whites to be MTM-eligible under the star ratings criteria. In addition, MTM eligibility criteria based on star ratings would reduce racial and ethnic disparities associated with MMA in the general Medicare population and those with specific chronic conditions. DISCLOSURES: Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under award number R01AG049696. The content of this study is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Cushman reports an Eli Lilly grant and uncompensated consulting for Takeda Pharmaceuticals outside this work. The other authors have no potential conflicts of interest to report. Study concept and design were contributed by Wang and Shih, along with Wan, Kuhle, Spivey, and Cushman. Wang, Qiao, and Wan took the lead in data collection, with assistance from the other authors. Data interpretation was performed by Wang, Kuhle, and Qiao, with assistance from the other authors. The manuscript was written by Spivey and Qiao, along with the other authors, and revised by Cushman, Dagogo-Jack, and Chisholm-Burns, along with the other authors.

Entities:  

Mesh:

Year:  2018        PMID: 29384031      PMCID: PMC5793919          DOI: 10.18553/jmcp.2018.24.2.97

Source DB:  PubMed          Journal:  J Manag Care Spec Pharm


  34 in total

1.  Trends in Antihypertensive Medication Discontinuation and Low Adherence Among Medicare Beneficiaries Initiating Treatment From 2007 to 2012.

Authors:  Gabriel S Tajeu; Shia T Kent; Ian M Kronish; Lei Huang; Marie Krousel-Wood; Adam P Bress; Daichi Shimbo; Paul Muntner
Journal:  Hypertension       Date:  2016-07-18       Impact factor: 10.190

2.  Disparities in access to essential new prescription drugs between non-Hispanic whites, non-Hispanic blacks, and Hispanic whites.

Authors:  Junling Wang; Jason M Noel; Ilene H Zuckerman; Nancy A Miller; Fadia T Shaya; C Daniel Mullins
Journal:  Med Care Res Rev       Date:  2006-12       Impact factor: 3.929

3.  A framework for the study of access to medical care.

Authors:  L A Aday; R Andersen
Journal:  Health Serv Res       Date:  1974       Impact factor: 3.402

4.  Characteristics of older adults who meet the annual prescription drug expenditure threshold for medicare medication therapy management programs.

Authors:  Gregory W Daniel; Daniel C Malone
Journal:  J Manag Care Pharm       Date:  2007-03

5.  Historical trend of disparity implications of Medicare MTM eligibility criteria.

Authors:  Junling Wang; Yanru Qiao
Journal:  Res Social Adm Pharm       Date:  2012-10-10

6.  Chronic Obstructive Pulmonary Disease Illness and Medication Beliefs are Associated with Medication Adherence.

Authors:  Katherine Krauskopf; Alex D Federman; Minal S Kale; Keith M Sigel; Melissa Martynenko; Rachel O'Conor; Michael S Wolf; Howard Leventhal; Juan P Wisnivesky
Journal:  COPD       Date:  2014-06-24       Impact factor: 2.409

7.  Diabetes Ten City Challenge: final economic and clinical results.

Authors:  Toni Fera; Benjamin M Bluml; William M Ellis
Journal:  J Am Pharm Assoc (2003)       Date:  2009 May-Jun

8.  Implementation and Clinical Outcomes of an Employer-Sponsored, Pharmacist-Provided Medication Therapy Management Program.

Authors:  Katie M Theising; Traci L Fritschle; Angelina M Scholfield; Emily L Hicks; Michelle L Schymik
Journal:  Pharmacotherapy       Date:  2015-11-02       Impact factor: 4.705

9.  The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia.

Authors:  Barry A Bunting; Benjamin H Smith; Susan E Sutherland
Journal:  J Am Pharm Assoc (2003)       Date:  2008 Jan-Feb

10.  Racial disparities in prescription drug use among dually eligible beneficiaries.

Authors:  Jennifer Schore; Randall Brown; Bridget Lavin
Journal:  Health Care Financ Rev       Date:  2003
View more
  4 in total

1.  Comparative Effectiveness of Medication Therapy Management Eligibility Criteria Across Racial/Ethnic Groups.

Authors:  Christina A Spivey; Yanru Qiao; Junling Wang; Ya-Chen Tina Shih; Jim Y Wan; Samuel Dagogo-Jack; William C Cushman; Lisa E Hines; Marie A Chisholm-Burns
Journal:  J Am Geriatr Soc       Date:  2019-01-23       Impact factor: 5.562

2.  Racial/ethnic disparities in the enrollment of Medication Therapy Management programs among Medicare beneficiaries with Alzheimer's disease and related dementias.

Authors:  Jamie A Browning; Chi Chun Steve Tsang; Rose Zeng; Xiaobei Dong; Joseph Garuccio; Jim Y Wan; Marie A Chisholm-Burns; Christopher K Finch; Jack W Tsao; Junling Wang
Journal:  Curr Med Res Opin       Date:  2022-08-09       Impact factor: 2.705

3.  Predictive Value Positive of MTM Eligibility Criteria under MMA and ACA in Identifying Individuals with Medication Utilization Issues.

Authors:  Yanru Qiao; Christina A Spivey; Junling Wang; Ya-Chen Tina Shih; Jim Y Wan; Julie Kuhle; Samuel Dagogo-Jack; William C Cushman; Marie Chisholm-Burns
Journal:  J Pharm Health Serv Res       Date:  2018-09-07

Review 4.  Evolution of the Medicare Part D Medication Therapy Management Program from Inception in 2006 to the Present.

Authors:  Cori Gray; Catherine E Cooke; Nicole Brandt
Journal:  Am Health Drug Benefits       Date:  2019-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.